Enterprise Value
18.27M
Cash
103.9M
Avg Qtr Burn
-5.726M
Short % of Float
6.14%
Insider Ownership
0.04%
Institutional Own.
20.66%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Endoxifen Details Cancer, Breast cancer | Phase 2 Update | |
AT-301 Details COVID-19 | Failed Discontinued | |
AT-H201 Details COVID-19 | Failed Discontinued |